Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: A meta-analysis of randomized controlled trials: A review

Journal of Neurosurgery

Volumn 119, Issue 1, 2013, Pages 180-189

  Shen, Jian ^a   Pan, Jian Wei ^a   Fan, Zuo Xu ^a   Xiong, Xiao Xing ^b   Zhan, Ren Ya ^a,b  

^a Departments of Neurosurgery   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Aneurysm; Clazosentan; Meta analysis; Outcome; Subarachnoid hemorrhage; Vascular disorders; Vasospasm

Indexed keywords

CLAZOSENTAN; NIMODIPINE;

ANEMIA; ARTICLE; BRAIN INFARCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GLASGOW OUTCOME SCALE; HUMAN; HYPOTENSION; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); VASOSPASM;

DIOXANES; HUMANS; MORBIDITY; PYRIDINES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ENDOTHELIN A; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; TREATMENT OUTCOME; VASOSPASM, INTRACRANIAL;

EID: 84879943737     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2013.3.JNS121436     Document Type: Article

References (51)

1. Al-Khindi T, Macdonald RL, Schweizer TA: Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke 41:e519-e536, 2010
2. Asano T, Ikegaki I, Suzuki Y, Satoh S, Shibuya M: Endothelin and the production of cerebral vasospasm in dogs. Biochem Biophys Res Commun 159:1345-1351, 1989
3. Barth M, Capelle HH, Münch E, Thomé C, Fiedler F, Schmiedek P, et al: Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series. Acta Neurochir (Wien) 149:911-918, 2007
4. Beck J, Raabe A: Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction. Acta Neurochir Suppl 110:147-150, 2011
5. Bederson JB, Connolly ES Jr., Batjer HH, Dacey RG, Dion JE, Diringer MN, et al: Guidelines for the management of aneu- rysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 40:994-1025, 2009
6. Cahill J, Zhang JH: Subarachnoid hemorrhage: is it time for a new direction? Stroke 40 (3 Suppl):S86-S87, 2009
7. Castanares-Zapatero D, Hantson P: Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage. Ann Intensive Care 1:12, 2011
8. Chen G, Tariq A, Ai J, Sabri M, Jeon HJ, Tang EJ, et al: Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats. Brain Res 1392:132-139, 2011
9. Crowley RW, Medel R, Kassell NF, Dumont AS: New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. Drug Discov Today 13:254-260, 2008
10. de Oliveira JG, Beck J, Ulrich C, Rathert J, Raabe A, Seifert V: Comparison between clipping and coiling on the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurosurg Rev 30:22-31, 2007
11. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
12. Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, et al: Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 3:CD000277, 2007
13. Dreier JP, Woitzik J, Fabricius M, Bhatia R, Major S, Drenckhahn C, et al: Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain 129:3224-3237, 2006
14. Egge A, Waterloo K, Sjøholm H, Solberg T, Ingebrigsten T, Romner B: Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery 49: 593-606, 2001
15. Fergusen S, Macdonald RL: Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 60:658-667, 2007
16. Furlan AD, Pennick V, Bombardier C, van Tulder M: 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 34: 1929-1941, 2009
17. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al: GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64: 383-394, 2011
18. Hansen-Schwartz J, Hoel NL, Zhou M, Xu CB, Svendgaard NA, Edvinsson L: Subarachnoid hemorrhage enhances endothelin receptor expression and function in rat cerebral arteries. Neurosurgery 52:1188-1195, 2003
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003
20. Ibrahim GM, Vachhrajani S, Ilodigwe D, Kassell NF, Mayer SA, Ruefenacht D, et al: Method of aneurysm treatment does not affect clot clearance after aneurysmal subarachnoid hemorrhage. Neurosurgery 70:102-109, 2012
21. Kassell NF, Sasaki T, Colohan AR, Nazar G: Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 16:562-572, 1985
22. Kassell NF, Torner JC, Haley EC Jr., Jane JA, Adams HP, Kongable GL: The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J Neurosurg 73:18-36, 1990
23. Kessler IM, Pacheco YG, Lozzi SP, de Araújo AS Jr., Onishi FJ, de Mello PA: Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol 64 (Suppl 1): S1:2-S1:5, 2005
24. Kramer A, Fletcher J: Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage? A meta-analysis. Stroke 40:3403-3406, 2009
25. Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med 127:820-826, 1997
26. Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, et al: Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke 31:383-391, 2000
27. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al: Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 10:618-625, 2011
28. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al: Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 43:1463-1469, 2012
29. Macdonald RL, Hunsche E, Schüler R, Wlodarczyk J, Mayer SA: Quality of life and healthcare resource use associated with angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 43:1082-1088, 2012
30. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al: Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebocontrolled phase 2 dose-finding trial. Stroke 39:3015-3021, 2008
31. Macdonald RL, Pluta RM, Zhang JH: Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 3:256-263, 2007
32. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
33. Mascia L, Fedorko L, Stewart DJ, Mohamed F, terBrugge K, Ranieri VM, et al: Temporal relationship between endothelin- 1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke 32:1185-1190, 2001
34. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006-1012, 2009
35. Rabinstein AA, Lanzino G, Wijdicks EF: Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. Lancet Neurol 9:504-519, 2010
36. Rosengart AJ, Huo JD, Tolentino J, Novakovic RL, Frank JI, Goldenberg FD, et al: Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg 107:253-260, 2007
37. Ruane-O'Hora T, Rae MG, Markos F: Effect of clazosentan, a selective endothelin A receptor antagonist, and tezosentan, a dual endothelin A/B antagonist, on pulsatile shear stress induced constriction of the iliac in the anaesthetized pig. Clin Exp Pharmacol Physiol 38:515-520, 2011
38. Sabri M, Ai J, Macdonald RL: Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Stroke 42:1454-1460, 2011
39. Sampson M, Barrowman NJ, Moher D, Klassen TP, Pham B, Platt R, et al: Should meta-analysts search Embase in addition to Medline? J Clin Epidemiol 56:943-955, 2003
40. Schubert GA, Schilling L, Thomé C: Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. Laboratory investigation. J Neurosurg 109:1134-1140, 2008
41. Scott RB, Eccles F, Molyneux AJ, Kerr RS, Rothwell PM, Carpenter K: Improved cognitive outcomes with endovascular coiling of ruptured intracranial aneurysms: neuropsychologi cal outcomes from the International Subarachnoid Aneurysm Trial (ISAT). Stroke 41:1743-1747, 2010
42. Shaw MM, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM: Efficacy and safety of the ETA/B receptor antagonist TAK-044 in treating subarachnoid hemorrhage. J Neurosurg 93:992-997, 2000
43. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al: Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103:9-17, 2005
44. van Tulder M, Furlan A, Bombardier C, Bouter L: Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine (Phila Pa 1976) 28:1290-1299, 2003
45. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Schilling L, Seifert V: Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction. J Neurosurg 102:1101-1107, 2005
46. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Seifert V, Schilling L: Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelin(B) receptor-mediated relaxation. J Neurosurg 102:1108-1114, 2005
47. Vergouwen MD, Ilodigwe D, Macdonald RL: Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 42:924-929, 2011
48. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB: Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 28:1761-1770, 2008
49. Weyer GW, Nolan CP, Macdonald RL: Evidence-based cerebral vasospasm management. Neurosurg Focus 21(3):E8, 2006
50. Xie A, Aihara Y, Bouryi VA, Nikitina E, Jahromi BS, Zhang ZD, et al: Novel mechanism of endothelin-1-induced vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 27:1692-1701, 2007
51. Zimmermann M, Seifert V: Endothelin receptor antagonists and cerebral vasospasm. Clin Auton Res 14:143-145, 2004